Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy

Osteoporosis is age-related deterioration in bone mass and micro-architecture. Denosumab is a novel human monoclonal antibody for osteoporosis. It is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor, which binds to and inhibits osteoblast-produced RANKL, in turn reduces the binding...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Cell Dev Biol
Autors principals: Zhang, Ning, Zhang, Zong-Kang, Yu, Yuanyuan, Zhuo, Zhenjian, Zhang, Ge, Zhang, Bao-Ting
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Cell and Developmental Biology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7240042/
https://ncbi.nlm.nih.gov/pubmed/32478071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2020.00325
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars